191 research outputs found
Estudio de pilotos automáticos enfocados en la configuración de ala volante para vehÃculos aéreos no tripulados
Este artÃculo presenta una revisión de los sistemas de piloto automáticos para vehÃculos aéreos no tripulados (UAV). Se muestra un estudio de los productos comerciales que se pueden encontrar actualmente en el mercado, se incluyen sistemas open source y se hace una comparación entre las diferentes arquitecturas a nivel de requerimientos básicos a nivel de sensores, capacidad de procesamiento, tamaño, peso y precios. Este estudio se realiza con el fin de analizar la arquitectura básica que tienen estos tipos de sistemas enfocados hacia la configuración de un UAV de tipo ala volante
Using the Social-Local-Mobile App for Smoking Cessation in the SmokeFreeBrain Project: Protocol for a Randomized Controlled Trial
Background: Smoking is considered the main cause of preventable illness and early deaths worldwide. The treatment usually prescribed to people who wish to quit smoking is a multidisciplinary intervention, combining both psychological advice and pharmacological therapy, since the application of both strategies significantly increases the chance of success in a quit attempt.
Objective: We present a study protocol of a 12-month randomized open-label parallel-group trial whose primary objective is to analyze the efficacy and efficiency of usual psychopharmacological therapy plus the Social-Local-Mobile app (intervention group) applied to the smoking cessation process compared with usual psychopharmacological therapy alone (control group).
Methods: The target population consists of adult smokers (both male and female) attending the Smoking Cessation Unit at Virgen del RocÃo University Hospital, Seville, Spain. Social-Local-Mobile is an innovative intervention based on mobile technologies and their capacity to trigger behavioral changes. The app is a complement to pharmacological therapies to quit smoking by providing personalized motivational messages, physical activity monitoring, lifestyle advice, and distractions (minigames) to help overcome cravings. Usual pharmacological therapy consists of bupropion (Zyntabac 150 mg) or varenicline (Champix 0.5 mg or 1 mg). The main outcomes will be (1) the smoking abstinence rate at 1 year measured by means of exhaled carbon monoxide and urinary cotinine tests, and (2) the result of the cost-effectiveness analysis, which will be expressed in terms of an incremental cost-effectiveness ratio. Secondary outcome measures will be (1) analysis of the safety of pharmacological therapy, (2) analysis of the health-related quality of life of patients, and (3) monitoring of healthy lifestyle and physical exercise habits.
Results: Of 548 patients identified using the hospital’s electronic records system, we excluded 308 patients: 188 declined to participate and 120 did not meet the inclusion criteria. A total of 240 patients were enrolled: the control group (n=120) will receive usual psychopharmacological therapy, while the intervention group (n=120) will receive usual psychopharmacological therapy plus the So-Lo-Mo app. The project was approved for funding in June 2015. Enrollment started in October 2016 and was completed in October 2017. Data gathering was completed in November 2018, and data analysis is under way. The first results are expected to be submitted for publication in early 2019.
Conclusions: Social networks and mobile technologies influence our daily lives and, therefore, may influence our smoking habits as well. As part of the SmokeFreeBrain H2020 European Commission project, this study aims at elucidating the potential role of these technologies when used as an extra aid to quit smoking
Batumi Raptor Count: autumn raptor migration count data from the Batumi bottleneck, Republic of Georgia
A Mobile Health Solution Complementing Psychopharmacology-Supported Smoking Cessation: Randomized Controlled Trial
Background: Smoking cessation is a persistent leading public health challenge. Mobile health (mHealth) solutions are emerging
to improve smoking cessation treatments. Previous approaches have proposed supporting cessation with tailored motivational
messages. Some managed to provide short-term improvements in smoking cessation. Yet, these approaches were either static in
terms of personalization or human-based nonscalable solutions. Additionally, long-term effects were neither presented nor assessed
in combination with existing psychopharmacological therapies.
Objective: This study aimed to analyze the long-term efficacy of a mobile app supporting psychopharmacological therapy for
smoking cessation and complementarily assess the involved innovative technology.
Methods: A 12-month, randomized, open-label, parallel-group trial comparing smoking cessation rates was performed at Virgen
del RocÃo University Hospital in Seville (Spain). Smokers were randomly allocated to a control group (CG) receiving usual care
(psychopharmacological treatment, n=120) or an intervention group (IG) receiving psychopharmacological treatment and using
a mobile app providing artificial intelligence–generated and tailored smoking cessation support messages (n=120). The secondary
objectives were to analyze health-related quality of life and monitor healthy lifestyle and physical exercise habits. Safety was
assessed according to the presence of adverse events related to the pharmacological therapy. Per-protocol and intention-to-treat
analyses were performed. Incomplete data and multinomial regression analyses were performed to assess the variables influencing
participant cessation probability. The technical solution was assessed according to the precision of the tailored motivational
smoking cessation messages and user engagement. Cessation and no cessation subgroups were compared using t tests. A voluntary
satisfaction questionnaire was administered at the end of the intervention to all participants who completed the trial.
Results: In the IG, abstinence was 2.75 times higher (adjusted OR 3.45, P=.01) in the per-protocol analysis and 2.15 times
higher (adjusted OR 3.13, P=.002) in the intention-to-treat analysis. Lost data analysis and multinomial logistic models showed
different patterns in participants who dropped out. Regarding safety, 14 of 120 (11.7%) IG participants and 13 of 120 (10.8%)
CG participants had 19 and 23 adverse events, respectively (P=.84). None of the clinical secondary objective measures showed relevant differences between the groups. The system was able to learn and tailor messages for improved effectiveness in supporting
smoking cessation but was unable to reduce the time between a message being sent and opened. In either case, there was no
relevant difference between the cessation and no cessation subgroups. However, a significant difference was found in system
engagement at 6 months (P=.04) but not in all subsequent months. High system appreciation was reported at the end of the study.
Conclusions: The proposed mHealth solution complementing psychopharmacological therapy showed greater efficacy for
achieving 1-year tobacco abstinence as compared with psychopharmacological therapy alone. It provides a basis for artificial
intelligence–based future approaches.
Trial Registration: ClinicalTrials.gov NCT03553173; https://clinicaltrials.gov/ct2/show/NCT03553173
International Registered Report Identifier (IRRID): RR2-10.2196/12464H2020 European Commission research and innovation program grant agreement 68112
Protective role of vitamin B6 (PLP) against DNA damage in Drosophila models of type 2 diabetes
Growing evidence shows that improper intake of vitamin B6 increases cancer risk and several studies indicate that diabetic patients have a higher risk of developing tumors. We previously demonstrated that in Drosophila the deficiency of Pyridoxal 5' phosphate (PLP), the active form of vitamin B6, causes chromosome aberrations (CABs), one of cancer prerequisites, and increases hemolymph glucose content. Starting from these data we asked if it was possible to provide a link between the aforementioned studies. Thus, we tested the effect of low PLP levels on DNA integrity in diabetic cells. To this aim we generated two Drosophila models of type 2 diabetes, the first by impairing insulin signaling and the second by rearing flies in high sugar diet. We showed that glucose treatment induced CABs in diabetic individuals but not in controls. More interestingly, PLP deficiency caused high frequencies of CABs in both diabetic models demonstrating that hyperglycemia, combined to reduced PLP level, impairs DNA integrity. PLP-depleted diabetic cells accumulated Advanced Glycation End products (AGEs) that largely contribute to CABs as α-lipoic acid, an AGE inhibitor, rescued not only AGEs but also CABs. These data, extrapolated to humans, indicate that low PLP levels, impacting on DNA integrity, may be considered one of the possible links between diabetes and cancer
FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells
Receptor Tyrosine Kinases (RTKs) and Focal Adhesion Kinase (FAK) regulate multiple signalling pathways, including mitogen-activated protein (MAP) kinase pathway. FAK interacts with several RTKs but little is known about how FAK regulates their downstream signalling. Here we investigated how FAK regulates signalling resulting from the overexpression of the RTKs RET and EGFR. FAK suppressed RTKs signalling in Drosophila melanogaster epithelia by impairing MAPK pathway. This regulation was also observed in MDA-MB-231 human breast cancer cells, suggesting it is a conserved phenomenon in humans. Mechanistically, FAK reduced receptor recycling into the plasma membrane, which resulted in lower MAPK activation. Conversely, increasing the membrane pool of the receptor increased MAPK pathway signalling. FAK is widely considered as a therapeutic target in cancer biology; however, it also has tumour suppressor properties in some contexts. Therefore, the FAK-mediated negative regulation of RTK/MAPK signalling described here may have potential implications in the designing of therapy strategies for RTK-driven tumours
Efficient distributed tag-based encryption and its application to group signatures with efficient distributed traceability
In this work, we first formalize the notion of dynamic group signatures with distributed traceability, where the capability to trace signatures is distributed among n managers without requiring any interaction. This ensures that only the participation of all tracing managers permits tracing a signature, which reduces the trust placed in a single tracing manager. The threshold variant follows easily from our definitions and constructions. Our model offers strong security requirements. Our second contribution is a generic construction for the notion which has a concurrent join protocol, meets strong security requirements, and offers efficient traceability, i.e. without requiring tracing managers to produce expensive zero-knowledge proofs for tracing correctness. To dispense with the expensive zero-knowledge proofs required in the tracing, we deploy a distributed tag-based encryption with public verifiability. Finally, we provide some concrete instantiations, which, to the best of our knowledge, are the first efficient provably secure realizations in the standard model simultaneously offering all the aforementioned properties. To realize our constructions efficiently, we construct an efficient distributed (and threshold) tag-based encryption scheme that works in the efficient Type-III asymmetric bilinear groups. Our distributed tag-based encryption scheme yields short ciphertexts (only 1280 bits at 128-bit security), and is secure under an existing variant of the standard decisional linear assumption. Our tag-based encryption scheme is of independent interest and is useful for many applications beyond the scope of this paper. As a special case of our distributed tag-based encryption scheme, we get an efficient tag-based encryption scheme in Type-III asymmetric bilinear groups that is secure in the standard model
Differential roles of the Drosophila EMT-inducing transcription factors Snail and Serpent in driving primary tumour growth.
Several transcription factors have been identified that activate an epithelial-to-mesenchymal transition (EMT), which endows cells with the capacity to break through basement membranes and migrate away from their site of origin. A key program in development, in recent years it has been shown to be a crucial driver of tumour invasion and metastasis. However, several of these EMT-inducing transcription factors are often expressed long before the initiation of the invasion-metastasis cascade as well as in non-invasive tumours. Increasing evidence suggests that they may promote primary tumour growth, but their precise role in this process remains to be elucidated. To investigate this issue we have focused our studies on two Drosophila transcription factors, the classic EMT inducer Snail and the Drosophila orthologue of hGATAs4/6, Serpent, which drives an alternative mechanism of EMT; both Snail and GATA are specifically expressed in a number of human cancers, particularly at the invasive front and in metastasis. Thus, we recreated conditions of Snail and of Serpent high expression in the fly imaginal wing disc and analysed their effect. While either Snail or Serpent induced a profound loss of epithelial polarity and tissue organisation, Serpent but not Snail also induced an increase in the size of wing discs. Furthermore, the Serpent-induced tumour-like tissues were able to grow extensively when transplanted into the abdomen of adult hosts. We found the differences between Snail and Serpent to correlate with the genetic program they elicit; while activation of either results in an increase in the expression of Yorki target genes, Serpent additionally activates the Ras signalling pathway. These results provide insight into how transcription factors that induce EMT can also promote primary tumour growth, and how in some cases such as GATA factors a ‘multi hit’ effect may be achieved through the aberrant activation of just a single gene
A Feed-Forward Circuit Linking Wingless, Fat-Dachsous Signaling, and the Warts-Hippo Pathway to Drosophila Wing Growth
The secreted morphogen Wingless promotes Drosophila wing growth by fueling a wave front of Fat-Dachsous signaling that recruits new cells into the wing primordium
Cómo cuantificar los aspectos cualitativos en escalas de clasificación de resultados NOC para etiquetas psico-socioculturales
- …